Promising Phase 1 Results of IDE849: A Potential Breakthrough in Treating Relapsed Small Cell Lung Cancer

IDE849 (SHR-4849) Shows Promising Results in Phase 1 Study at ESMO 2026

Overview of Recent Findings

IDEAYA Biosciences, Inc. unveiled compelling results from their updated Phase 1 clinical trial of IDE849, an innovative antibody-drug conjugate (ADC) targeting delta-like ligand 3 (DLL3), at the European Society for Medical Oncology (ESMO) Congress 2026. The findings suggest IDE849 holds significant anti-tumor activity and favorable overall survival rates for patients suffering from relapsed small cell lung cancer (SCLC) and neuroendocrine carcinomas (NECs).

At the data cutoff on August 21, 2026, 122 patients had been enrolled in the study, with 103 diagnosed with SCLC and 19 with NECs. Remarkably, the study indicated a median overall survival (OS) of 17.4 months for patients undergoing second-line therapy for SCLC and 14.7 months for patients treated at both the second and third-line levels.

Efficacy Insights

In the second-line SCLC cohort, out of 51 participants, a substantial overall response rate (ORR) of 72.5% was recorded, in addition to a confirmed overall response rate (cORR) of 60.8%. Patients with greater treatment history (≥3L) shown an ORR of 68.3%. Furthermore, within a subgroup of patients with brain metastases, the treatment achieved an impressive 76.9% ORR, cementing IDE849's significance in this challenging patient population.

Efficacy was also observed in other NEC types, where the ORR reached 52.6% with a confirmed response rate of 36.8%, proving IDE849's potential relevance beyond just SCLC. The findings revealed disease control rates soared to 84.2% with a median progression-free survival (PFS) of 7.0 months, exemplifying the drug's promise in combating these malignancies.

Safety Profile

Regarding safety, the treatment was generally well-tolerated. Among patients treated at the expansion dose of 2.4 mg/kg, adverse events of Grade 3 or higher were observed in 33.3% of patients. Despite this, the incidence of treatment-related discontinuations remained notably low at 2.5%, signaling a manageable safety profile. Participants primarily experienced hematologic side effects, such as neutropenia, which aligns with prior studies on similar drug types.

In an ongoing global Phase 1/2 trial, additional expansions to establish the recommended Phase 3 dose are currently being evaluated, affirming IDEAYA's robust commitment to incorporating comprehensive safety evaluations in their drug development process.

Future Directions

IDEAYA is keenly focused on advancing this promising treatment. Following successful meetings with the U.S. FDA discussing plans for Phase 3 trials, the company seeks to address pressing unmet medical needs, particularly in relapsed SCLC and NEC settings. With increasing patient enrollment across various regions in their clinical studies, IDEAYA aims to unveil further clinical efficacy and safety updates by late 2026 or early 2027.

In conclusion, the promising results from ESMO 2026 underscore IDE849’s potential in revolutionizing treatment avenues for patients grappling with relapsed SCLC and neuroendocrine carcinomas, driving enthusiasm within the oncology community to explore its full therapeutic possibilities.